An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Harrow, a leading U.S. eyecare pharmaceutical company, will release its financial results for Q3 2023 on November 13, 2023. The company will also provide a business update during a conference call and live webcast at 4:45 p.m. Eastern Time. Participants can access the webcast on harrow.com.
Positive
None.
Negative
None.
NASHVILLE, Tenn.--(BUSINESS WIRE)--
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the third quarter ended September 30, 2023, on Monday, November 13, 2023, after the market close. The Company will also post its third quarter Letter to Stockholders to the “Investors” section of its website, harrow.com. Harrow will host a conference call and live webcast at 4:45 p.m. Eastern Time to discuss the results and provide a business update.
Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the U.S. market. Harrow helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans each year. For more information about Harrow, please visit harrow.com.
Jamie Webb
Director of Communications and Investor Relations
jwebb@harrowinc.com
615-733-4737
Source: Harrow, Inc.
FAQ
When will Harrow release its financial results for Q3 2023?
Harrow will release its financial results for Q3 2023 on November 13, 2023.
Where can I find Harrow's third quarter Letter to Stockholders?
Harrow's third quarter Letter to Stockholders can be found in the 'Investors' section of its website, harrow.com.
What is the date and time of the conference call and live webcast?
The conference call and live webcast will take place on Monday, November 13, 2023, at 4:45 p.m. Eastern Time.
How can I access the webcast?
Participants can access the webcast on harrow.com.
What are the participant dial-in numbers for the conference call?
For the conference call, the participant dial-in numbers are 1-833-953-2434 (U.S.) and 1-412-317-5763 (International).
What are the replay dial-in numbers for the conference call?
For the telephonic replay of the conference call (available through November 20, 2023), the dial-in numbers are 1-877-344-7529 (U.S.) and 1-412-317-0088 (International).
Until when can I access the online replay of the webcast?
The online replay of the webcast will be available through November 13, 2024.
harrow health, inc., together with its subsidiaries, develops, produces, and sells medications for unmet needs primarily in the united states. the company primarily provides ophthalmology based formulations to physicians and patients; and sterile and non-sterile compounded medications. it also develops and commercializes therapeutics for treating ocular surface diseases; and non-intravenous sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. its products portfolio includes topical eye drop drug candidates, including surf-100 and surf-200; surf-300, an oral capsule for treating patients suffering from ocular surface diseases, and ded signs and symptoms; klarity drops to protect and rehabilitate the ocular surface pathology for patients with ded; melt-100, a drug that is administered sublingually for conscious sedation during cataract surgery; may-66 that is used for the treatment of symptoms associated with peyronie's diseas
